Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155984 | 0.88 | ALDH1A1 (0.54) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL103235 | 0.88 | ALDH1A1 (0.54) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL104518 | 0.88 | ALDH1A1 (0.54) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| Methane SCHEMBL9122539 | 0.86 | ALDH1A1 (0.53) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| Bromide SCHEMBL6042642 | 0.86 | ALDH1A1 (0.53) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6178991 | 0.86 | ALDH1A1 (0.53) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL28215185 | 0.86 | ALDH1A1 (0.53) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL38660904 | 0.86 | ALDH1A1 (0.53) | GAAPKMKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL11363878 | 0.85 | PPARG (0.49) | PTGS2ALDH1A1L3MBTL1 | |
| SCHEMBL1815681 | 0.85 | PTGS2 (0.50) | PTGS2GAACYP1A2CYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | PTGS2 1321/4885GAA 1083/4885CYP1A2 1475/4885 |
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | PTGS2 3734/4885GAA 1312/4885CYP1A2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.